



Wockhardt Limited
Regd. Office:
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051, India
Phone : 91-22-2653 4444
Fax : 91-22-2653 4242
Website : www.wockhardt.com

April 22, 2004

Dear Shareowners,

I am pleased to address you once again. I had the opportunity to meet some of you at our recent **Annual General Meeting** in Mumbai. It was a happy occasion, as shareowners were all praise for the rapid progress made by the company in the past year 2003. We received unanimous **approval** for the board's proposal for the **issue of bonus shares, enhanced dividend and stock split**.

As you are aware, Wockhardt's board had proposed an issue of bonus shares on the basis of **one new share for every two existing shares**, and an **enhanced 75% dividend**. Our board also recommended **splitting the face value of shares from Rs. 10 to Rs. 5**. We, at Wockhardt, are gratified with the shareowners' response to the board's proposals, which aim at enhancing shareowner value and benefiting the retail shareowner community.


Your company has put in a strong performance in the first quarter of the year 2004. Wockhardt Limited has just announced its unaudited **consolidated financial results** for the **first quarter ending March 31, 2004**.

Net Profit stood at **Rs. 44 crores**, recording an impressive **441%** improvement over the corresponding period of 2003. Sales, at **Rs. 288 crores**, posted a **78%** increase over the first quarter of 2003. **Operating Margins** doubled to **20%** and **Operating Profit** at **Rs. 58 crores** saw a **266%** increase. Our total **biotechnology portfolio sales** increased by **67%** during the quarter.

This performance has made possible yet another landmark achievement ... with Wockhardt's **Consolidated Sales** crossing the **Rs. 1,000-crore mark** and **Profit Before Tax** passing the **Rs. 200-crore mark** on a moving annual basis.

International Business ... US and Europe drive stupendous growth :

International Business grew by **118%** during the quarter, raising the contribution to **61%** of **Wockhardt's consolidated sales**. The growth was driven by more than **200% increase in formulation business**. The **generics (ANDA) business in the US** posted a **37%** growth during the quarter. **CP Pharmaceuticals**, our UK-based subsidiary which we acquired last July, posted a **22% sales growth** during the quarter. Operating Profit as well as Margins have improved after the company came under Wockhardt management. Wockhardt has consolidated the businesses of Wallis Laboratory and CP Pharmaceuticals into a new entity, christened **Wockhardt UK Ltd**.



New US subsidiary to provide strategic thrust : Last week, we announced our decision to establish a **sales and marketing subsidiary** in the US, called **Wockhardt USA Inc**. This development will help achieve exponential growth in the world's largest pharmaceutical market in the next few years. Mr. Arthur Maher, a marketing professional with over 20 years of experience in the US generics business, has been appointed as President of Wockhardt USA Inc., to provide a new thrust to the US business.

Wockhardt's global Biotechnology Park is commissioned : Biotechnology products will play an increasingly major role in driving Wockhardt's topline and bottomline growth in the years to come. You will be happy to know that we have commissioned our world-class **Rs. 200-crore Biotech Park at Aurangabad**. The Park will provide Wockhardt with a powerful competitive edge to cater to the global requirements of biopharmaceuticals.

Indian Business shows robust growth: Wockhardt's **Domestic Business** returned to the growth path during the quarter, recording a **38% growth** over the first quarter of 2003. A strategic thrust on **power brands**, and the **diabetology** and **nephrology** portfolios has put the domestic business on the growth track.

Research & Development ... New chemical entities show great promise : Continuing its accent on R&D, your company invested **Rs. 12.5 crores in R&D** during the first quarter compared to Rs. 10.6 crores in the corresponding quarter of 2003. Our **new chemical entities** continued to make progress and are currently in various stages of clinical and pre-clinical trials.

On behalf of 3500 Wockhardians, let me thank you for your continued support -- it has been a great motivator for all of us.

Warm regards,

Habil Khorakiwala
Chairman

Wockhardt joins the Rs. 1000 crore league



- ◆ Consolidated revenue crosses Rs. 1000 crores (Rs. 10 billion) on moving annual basis
- ◆ Profit before tax crosses Rs. 200 crores
- ◆ International business grows by 118 %
- ◆ Biotech Park commissioned
- ◆ Biotech products' sales up 67%

QUARTER HIGHLIGHTS

- ▲ Net Profit up 441%
- ▲ Sales grow 78%
- ▲ Operating margins double
- ▲ Files 3 ANDAs

WOCKHARDT LIMITED - CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND MAT ENDED 31ST MARCH, 2004

(Rs. in Million)

MAT Ended 31/3/2003	% To Sales	MAT Ended 31/3/2004	% To Sales	% Growth	Particulars	Quarter Ended 31/3/2004	% Growth	Quarter Ended 31/3/2003
7540	100.0	10684	100.0	41.7	Sales	2883	78.1	1619
6324	83.9	8470	79.3	33.9	Operating Expenditure	2304	57.7	1461
1216	16.1	2214	20.7	82.1	EBITDA	579	266.5	158
69	0.9	(18)	(0.2)	(126.1)	Interest	(7)	(150.0)	14
192	2.5	303	2.8	57.8	Depreciation	88	66.0	53
17	-	75	-	-	Other Income & Extra Ordinary Item	3	-	3
972	12.9	2004	18.8	106.2	Profit Before Tax	501	433.0	94
97	1.3	216	2.1	122.7	Provision for Taxation	57	375.0	12
875	11.6	1788	16.7	104.3	Profit After Tax	444	441.5	82
363	-	363	-	-	Paid-up Equity Capital	363	-	363
24.13	-	49.24	-	104.1	Earning Per Share (Rs.)	12.23	441.2	2.26

Financial year of Wockhardt Limited is Jan - Dec

MAT = Moving Annual Total

In case you need any further clarification, please write to our Investor Service Cell, Wockhardt Limited, Wockhardt Towers, Bandra-Kurla Complex, Bandra East, Mumbai 400 051 or E-mail at rgandhi@wockhardt.com

Please do visit our corporate website www.wockhardt.com